Hikma Pharmaceuticals PLC
HKMPY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,658 | $1,558 | $1,569 | $1,436 |
| % Growth | 6.4% | -0.7% | 9.2% | – |
| Cost of Goods Sold | $933 | $899 | $813 | $813 |
| Gross Profit | $725 | $610 | $756 | $623 |
| % Margin | 43.7% | 39.1% | 48.2% | 43.4% |
| R&D Expenses | $73 | $79 | $61 | $84 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $278 | $296 | $280 | $415 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $115 | $23 | $64 | -$1 |
| Operating Expenses | $466 | $398 | $405 | $498 |
| Operating Income | $259 | $235 | $351 | $125 |
| % Margin | 15.6% | 15.1% | 22.4% | 8.7% |
| Other Income/Exp. Net | $36 | -$94 | -$64 | -$47 |
| Pre-Tax Income | $295 | $167 | $287 | $78 |
| Tax Expense | $55 | $34 | $59 | $18 |
| Net Income | $238 | $132 | $226 | $59 |
| % Margin | 14.4% | 8.5% | 14.4% | 4.1% |
| EPS | 2.16 | 1.2 | 2.04 | 0.54 |
| % Growth | 80% | -41.2% | 277.8% | – |
| EPS Diluted | 2.14 | 1.18 | 2.02 | 0.52 |
| Weighted Avg Shares Out | 111 | 110 | 112 | 111 |
| Weighted Avg Shares Out Dil | 111 | 112 | 112 | 111 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $4 | $4 | $4 |
| Interest Expense | $40 | $44 | $44 | $43 |
| Depreciation & Amortization | $102 | $100 | $96 | $94 |
| EBITDA | $476 | $309 | $427 | $214 |
| % Margin | 28.7% | 19.8% | 27.2% | 14.9% |